Почетна › Trostruko negativni rak dojke › Mičigen
Kliničke studije za Trostruko negativni rak dojke u državi Mičigen
28 studija za Trostruko negativni rak dojke traži učesnike na lokacijama u državi Mičigen.
Gradovi u državi Mičigen
Zvanični tekst studije (na engleskom)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06841354A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Karmanos Cancer Institute, Detroit
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07503808Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- START Midwest, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 9. 11. 2026. · NCT07652242A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07029399A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- START Midwest, LLC, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07318805Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- University of Michigan ( Site 0103), Ann Arbor
- Henry Ford Health ( Site 0010), Detroit
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06393374A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
- William Beaumont Hospital, Royal Oak
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- START Midwest /ID# 256581, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06084481First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Karmanos Cancer Institute, Detroit
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06799065A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Grand Rapids
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07115043177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT07189871A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- BAMF Health, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT07020117Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Trinity Health, Ann Arbor
Тражи се учесникОпсервациона студија
Узраст од 18 до 99 · Оба пола · Ажурирано 3. 9. 2026. · NCT07211178Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 8. 2026. · NCT05985655A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06926868Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- BAMF Health, Grand Rapids
Тражи се учесникФаза 1
Узраст од 18 до 100 · Оба пола · Ажурирано 29. 7. 2026. · NCT06562192A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
- Karmanos Cancer Institute, Farmington Hills
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT05208762A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Henry Ford Health Hospital, Detroit
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- START Midwest /ID# 248685, Grand Rapids
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 6. 2026. · NCT05005403BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- University of Michigan, Ann Arbor
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 15. 6. 2026. · NCT05768932I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Herbert-Herman Cancer Center, Sparrow Hospital, Lansing
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 5. 2026. · NCT01042379JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Henry Ford Health System, Detroit
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 1. 2026. · NCT05490472A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- University of Michigan, Ann Arbor
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2025. · NCT05902988CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Trinity Health-Michigan, Ypsilanti
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Жене · Ажурирано 7. 1. 2025. · NCT06230185Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.